Key result
Ticagrelor plus aspirin shows no benefit over clopidogrel plus aspirin after off-pump CABG.
Why the study?
The study sought to evaluate the outcomes of postoperative three-month dual antiplatelet therapy in patients with NSTE-ACS following OPCAB with exclusively arterial grafts.
Does aspirin + ticagrelor improve overall survival and reduce MACCE and major bleeding compared to aspirin + clopidogrel in patients with NSTE-ACS following OPCAB?
Observational (n=269)
No
Does aspirin + ticagrelor improve overall survival and reduce MACCE and major bleeding compared to aspirin + clopidogrel in patients with NSTE-ACS following OPCAB?
Three-month dual antiplatelet therapy with aspirin and ticagrelor showed similar outcomes to aspirin and clopidogrel regarding survival, MACCE, and major bleeding in NSTE-ACS patients after total arterial OPCAB.
Answers are grounded in this paper and cite their sources.
No outcome difference with ticagrelor- versus clopidogrel-based DAPT after arterial OPCAB; leaves open optimal regimen and requires randomized confirmation.
We sought to evaluate the outcomes of postoperative three-month dual antiplatelet therapy in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) following off-pump coronary artery bypass grafting (OPCAB) with exclusively arterial grafts. Between 2013–2016, dual antiplatelet therapy (DAPT) with either aspirin + clopidogrel (ASA + CPD group, n = 100) or aspirin + ticagrelor (ASA + TCG group, n = 169) was prescribed postoperatively in 269 NSTE-ACS patients after total arterial OPCAB. Patients with indications for other oral anticoagulants were excluded from the study. Three-month DAPT was completed in 259 patients (96%); ASA + CPD group (n = 94) vs. ASA + TCG group (n = 165). A one-to-one propensity score matching was performed. Unadjusted comparison between the groups showed no significant difference in overall survival (P = 0.253) and composite outcome of major adverse cerebrovascular and cardiovascular event (MACCE) and major bleeding (P = 0.276). The rate of freedom from composite outcome at one year in the ASA + CPD and ASA + TCG groups was 91 ± 3% and 93 ± 2%, respectively. In multivariable analysis, being in the ASA + TCG group did not increase the risk of the composite outcome of MACCE and major bleeding (P = 0.972, hazard ratio: 1.0, 95% confidence interval: 0.4–2.3). Propensity score-matched comparison (76 pairs) showed no significant difference in the overall survival (P = 0.423) and composite outcome between the groups (P = 0.442). In the setting of exclusive arterial grafting, post-OPCAB three-month DAPT showed acceptable outcomes in patients with NSTE-ACS. There was no significant difference in overall survival or composite outcome of MACCE and major bleeding between the ASA + CPD and ASA + TCG groups.
No takes yet. Share an insight, caveat, or question.
Chang et al. (2019) conducted an observational in Non-ST-elevation acute coronary syndrome (NSTE-ACS) undergoing total arterial off-pump coronary artery bypass grafting (OPCAB) (n=269). Aspirin + Ticagrelor vs. Aspirin 100 mg daily + Clopidogrel 75 mg daily was evaluated on Composite of major adverse cerebrovascular and cardiovascular events (MACCE: all-cause death, new myocardial infarction, target vessel revascularization, or stroke) and major bleeding (HR 0.99, 95% CI 0.43-2.28, p=0.972). Aspirin plus ticagrelor did not alter the risk of MACCE and major bleeding compared to aspirin plus clopidogrel after total arterial off-pump CABG.
Synapse has enriched 10 related papers. Consider them for comparative context: